Latest news about Trimurthi
Trimurthi
69.00
0.00(0.00%)
Company Performance:
View Company Insights1D0.00%
1M-11.38%
6M+13.58%
1Y+57.00%
5Y+767.92%
More news about Trimurthi
03Jun 26
Novelix promoters acquire 950,000 shares via warrant conversion
Promoters of Novelix Pharmaceuticals Limited strengthened their control by acquiring 950,000 equity shares through the conversion of warrants on May 29, 2026. Srinidhi Fine Chemicals LLP acquired 800,000 shares, increasing its holding to 33.07%, while Narahari Belide acquired 150,000 shares, reaching a 3.35% stake. The company's equity share capital rose to ₹238,950,000 following the preferential allotment.
30May 26
Novelix Pharmaceuticals re-appoints V R P S & Co. as internal auditor
Novelix Pharmaceuticals Limited's board re-appointed M/s V R P S & Co. Chartered Accountants as internal auditor for FY 2026-27 on May 29, 2026, ensuring compliance with the Companies Act and SEBI regulations.
09Apr 26
Novelix Pharmaceuticals Submits Q4FY26 SEBI Compliance Certificate for Dematerialisation Process
Novelix Pharmaceuticals Limited filed its Q4FY26 compliance certificate under SEBI Depositories Regulations on April 9, 2026. The certificate, issued by R&T Agent Venture Capital and Corporate Investments Private Limited, confirms proper dematerialisation procedures for the quarter ended March 31, 2026, including timely updating of NSDL and CDSL records within the mandated 15-day period.
02Apr 26
Novelix Pharmaceuticals Files SEBI Disclosure for 11.50 Lakh Share Allotment
Novelix Pharmaceuticals Limited has completed regulatory filings under SEBI Takeover Regulations following the allotment of 11.50 lakh equity shares through warrant conversion to promoter group entities. The allotment raised Rs. 1.73 crore and increased the combined promoter group holding to 36.76% of the company's expanded share capital.
01Apr 26
Novelix Pharmaceuticals Reconstitutes Key Board Committees Following March 30, 2026 Meeting
Novelix Pharmaceuticals Limited reconstituted three key board committees on March 30, 2026, including the Audit Committee, Nomination & Remuneration Committee, and Stakeholders Relationship Committee. Janardhan Das Kabra was appointed Chairperson of both the Audit and Nomination & Remuneration Committees, while Sridevi Belide chairs the Stakeholders Relationship Committee. The restructuring ensures regulatory compliance under SEBI (LODR) Regulations, 2015, with all changes effective immediately.
18Feb 26
Novelix Pharmaceuticals Completes Preferential Share Allotment Under SEBI Regulations
Novelix Pharmaceuticals has completed a preferential share allotment of 3,30,000 equity shares to non-promoter investor Mallela Venkataramna Reddy, with formal regulatory disclosures submitted to BSE Limited. The transaction increased Reddy's shareholding from 8.52% to 9.18% and expanded the company's share capital from ₹176,150,000 to ₹199,350,000, demonstrating regulatory compliance and investor confidence.
18Feb 26
Novelix Pharmaceuticals Allots 3,25,000 Equity Shares to Promoter Group Member
Novelix Pharmaceuticals Limited completed a preferential allotment of 3,25,000 equity shares to promoter group member Vupparapalli Pavani on 12th February 2026, representing 1.63% of total share capital. This increased Pavani's shareholding from 4,00,000 shares (2.27%) to 7,25,000 shares (3.64%). The company's equity capital expanded from Rs. 176,150,000 to Rs. 199,350,000, and all regulatory disclosures under SEBI takeover regulations have been filed with BSE Limited.
14Feb 26
Novelix Pharmaceuticals Submits Revised Q3FY26 Financial Results to BSE
Novelix Pharmaceuticals Limited submitted revised Q3FY26 financial results to BSE, correcting typographical errors in the auditor's report. The company reported strong performance with income from operations of ₹4,840.25 lakhs and net profit of ₹100.44 lakhs for Q3FY26, showing significant growth from the previous year. The results were approved by the Board of Directors on February 12, 2026.
19Jan 26
Novelix Pharmaceuticals Allots 400,000 Equity Shares Upon Warrant Conversion, Raises ₹60.00 Lakhs
Novelix Pharmaceuticals Limited allotted 400,000 equity shares at ₹20.00 per share upon warrant conversion on January 19, 2026, raising ₹60.00 lakhs from three strategic investors. The company's paid-up capital increased from ₹172.15 crores to ₹176.15 crores. The Board also appointed Mr. Gnana Prakash Gattu as Nodal Officer under IEPF Rules.
11Jan 26
Novelix Pharmaceuticals Appoints Ms. Sridevi Belide as Non-Executive Non-Independent Director
Novelix Pharmaceuticals Limited has appointed Ms. Sridevi Belide as Non-Executive Non-Independent Director, effective October 23, 2025. The appointment was approved by shareholders in an Extraordinary General Meeting on January 9, 2026. Ms. Belide, an MBBS degree holder from the promoter group, brings healthcare expertise to the board while maintaining compliance with all regulatory requirements.
10Jan 26
Novelix Pharmaceuticals Shareholders Approve Appointment of Sridevi Belide as Non-Executive Director
Novelix Pharmaceuticals Limited shareholders approved Ms. Sridevi Belide's appointment as Non-Executive Non-Independent Director in an EGM on January 9, 2026. The appointment was effective from October 23, 2025, with Ms. Belide belonging to the promoter group. The company has completed all regulatory disclosures under SEBI regulations.
10Jan 26
Novelix Pharmaceuticals Limited Announces Unanimous Approval of EGM Resolutions
Novelix Pharmaceuticals Limited successfully conducted its Extra Ordinary General Meeting on January 09, 2026, through video conferencing with both proposed resolutions receiving unanimous shareholder approval. The meeting addressed equity share issuance on preferential basis and director appointment confirmation, with 86 shareholders participating in e-voting representing 62.87% of outstanding shares. All 10,147,138 votes cast were in favor of both resolutions, demonstrating strong shareholder confidence in the company's strategic decisions.
09Jan 26
Novelix Pharmaceuticals Limited Conducts Extra Ordinary General Meeting on January 9, 2026
Novelix Pharmaceuticals Limited held an Extra Ordinary General Meeting on January 9, 2026, via video conferencing from 3:30 PM to 3:56 PM with 64 members in attendance. The meeting addressed two key resolutions: issuing equity shares on a preferential basis (Special Resolution) and confirming Ms. Sridevi Belide's appointment as Additional Director (Ordinary Resolution). The company provided remote e-voting facilities from January 6-8, 2026, with CDSL support and Mr. Bharat Khaniwal as Scrutinizer, ensuring full regulatory compliance under SEBI regulations.
26Dec 25
Novelix Pharmaceuticals Reports Share Acquisition Under SEBI Regulation 29
Sesha Sai Nikhil Chintalapati acquired 4,92,000 equity shares in Novelix Pharmaceuticals Limited through preferential allotment on December 24, 2025, increasing his shareholding from 3.10% to 5.78%. The acquisition was disclosed under SEBI Regulation 29(1) requirements, with the company's equity capital standing at ₹17.21 crores comprising 17,215,000 shares. The disclosure also identifies DM Fincon Services LLP as a person acting in concert, maintaining their existing 20,000 share position.
24Dec 25
Novelix Pharmaceuticals Allots 10.74 Lakh Equity Shares Upon Warrant Conversion
Trimurthi has allotted 10,74,000 equity shares at ₹20 per share upon conversion of warrants, raising ₹2.15 crores. The allotment was distributed among four investors, including one from the promoter group. This conversion increases the company's paid-up capital from ₹16.14 crores to ₹17.22 crores, representing a significant capital expansion for the pharmaceutical firm.
21Dec 25
Novelix Pharmaceuticals Signs 5-Year Lab Lease Deal at Genome Valley
Trimurthi has signed a lease deed with Neovantage Innovation Park Private Limited for 3,890 square feet of laboratory space in Genome Valley, Hyderabad. The 5-year lease, starting January 1, 2026, will cost ₹272,300 monthly with a 5% annual increase. This facility will serve as Trimurthi's research and development center for pharmaceutical and biotechnology initiatives. The company confirmed this is not a related party transaction and has informed BSE Limited as per SEBI regulations.
15Dec 25
Novelix Pharmaceuticals Issues EGM Notice for ₹15 Crore Preferential Allotment
Trimurthi has announced an EGM on January 9, 2026, to seek approval for a ₹15 crore preferential allotment of 25,00,000 equity shares at ₹60 each. The allotment involves 40 investors, including promoters and non-promoters. Major allocations include 3,30,000 shares to Venkata Ramana Reddy Mallela and 3,25,000 to Pavani Vupparapalli. Funds will be used for technology transfer, lab setup, equipment procurement, and working capital. The EGM will also confirm Ms. Sridevi Belide's appointment as Non-Executive Non-Independent Director.
08Dec 25
Trimurthi Closes Trading Window Ahead of Fund-Raising Discussion
Trimurthi has closed its trading window for designated persons and their immediate relatives in compliance with SEBI regulations. The closure precedes a board meeting scheduled to discuss fund-raising proposals. The exact date of the meeting has not been disclosed.
14Nov 25
Trimurthi Reports Robust Q2 FY2026 Results with Net Profit of Rs 52.47 Crore
Trimurthi, an active pharmaceutical ingredients manufacturer and trader, announced unaudited financial results for Q2 FY2026. The company's total income rose to Rs 3,639.14 crore from Rs 387.37 crore in Q2 FY2025. Net profit increased to Rs 52.47 crore from Rs 12.95 crore. Half-year total income stood at Rs 5,874.26 crore with a net profit of Rs 64.03 crore. The company's balance sheet showed total assets of Rs 7,180.33 crore and total equity of Rs 2,560.96 crore. Ms. Monam Kapoor resigned as Independent Non-Executive Director.
23Oct 25
Trimurthi Appoints New Director and Allots 16.61 Lakh Equity Shares
Trimurthi's Board approved two key actions on October 23, 2025. Ms. Sridevi Belide, an MBBS holder related to the promoter group, was appointed as Additional Non-Executive Non-Independent Director. The company allotted 16,61,000 equity shares at Rs. 20 per share, raising Rs. 3.32 crore from 19 investors. This allotment, part of a larger warrant conversion, increased the paid-up equity capital from Rs. 14.48 crore to Rs. 16.14 crore, with total equity shares rising from 1.44 crore to 1.61 crore.
16Oct 25
Novelix Pharmaceuticals Partners with German Research Institute for Astaxanthin Production
Trimurthi has formed a technology transfer partnership with GMBU e.V., a German research institution, to advance large-scale production of Astaxanthin. The collaboration will take place at Novelix's laboratories in Hyderabad, India. GMBU e.V. will provide proprietary technology for cultivating Haematococcus pluvialis, while Novelix will offer financial and infrastructural support. Novelix plans to establish a GMP-certified production facility in Hyderabad, targeting markets in Europe, North America, and India. Astaxanthin, known for its strong antioxidant properties, has potential applications in various health areas including anti-diabetic, anti-inflammatory, neuroprotective, cardiovascular, ocular, and dermatological treatments.
21Sept 25
Novelix Pharmaceuticals Appoints New Directors and Secretarial Auditor
Trimurthi Limited, a Hyderabad-based pharmaceutical company, held its 31st Annual General Meeting on September 19, 2025. The company appointed two new directors: Mr. Gattu Gnana Prakash as Non-Executive Non-Independent Director and Ms. Mayuri Baidya as Non-Executive Independent Director. M/s Khushbu Kanwar & Co. was appointed as the Secretarial Auditor for a five-year term. All resolutions, including new appointments and corporate actions, were passed with overwhelming majority. Other approved actions include adopting financial statements, re-appointing a director, increasing borrowing limits, and authorizing various financial transactions.
11Aug 25
Novelis Reports 36% Drop in Q1 Net Income Despite 13% Sales Growth
Trimurthi, a Hindalco Industries subsidiary, reported mixed Q1 financial results. Net sales increased 13% to $4.70 billion, while net income fell 36% to $96.00 million. Rolled product shipments grew 1% to 963 kilotonnes. Adjusted EBITDA decreased 17% to $416.00 million, but operating cash flow improved 42% to $105.00 million. Higher aluminum prices boosted sales, but profitability was impacted by restructuring charges, higher scrap prices, unfavorable product mix, and negative tariff effects. Capital expenditures totaled $386.00 million, mainly for the new Bay Minette, Alabama plant. The company maintained strong liquidity at $3.00 billion with a net leverage ratio of 3.2x. CEO Steve Fisher noted strong demand for beverage packaging amid headwinds from higher scrap prices.
Industry Peers
Medplus Health Services
Entero Healthcare SolutionsTrimurthi
Vijaypd Ceutical
720.90
(-0.01%)
1,215.50
(-0.55%)
69.00
(0.0%)
66.50
(+2.31%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
